BrightGene Bio-Medical Technology Co., Ltd. clinical trial pipeline

11 trials changed in the last 30 days: 0 stopped, 4 with notable changes, 7 with minor changes only.

1. Notable

   BGM0504 · Type 2 Diabetes

   Primary completion pushed from Mar 20, 2026 to Nov 14, 2026

   Also in this update: Enrollment closed, study ongoing

   BrightGene Bio-Medical Technology Co., Ltd.·Phase 3· NCT06716216· Registry history of NCT06716216 on ClinicalTrials.gov (opens the registry)

   Oct 15, 2026

2. Notable

   BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only…BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise

   Primary completion pushed from Dec 29, 2025 to Nov 14, 2026

   Also in this update: Enrollment closed, study ongoing; Study completion pushed from Aug 25, 2026 to Nov 14, 2026

   BrightGene Bio-Medical Technology Co., Ltd.·Phase 3· NCT06716203· Registry history of NCT06716203 on ClinicalTrials.gov (opens the registry)

   Oct 15, 2026

3. Notable

   BGM0504 · Type 2 Diabetes in Indonesia

   Primary and study completion pushed from Jul 31, 2026 to Apr 30, 2027

   Also in this update: Enrollment closed, study ongoing; Final enrollment: 152 participants (planned 477)

   BrightGene Bio-Medical Technology Co., Ltd.·Phase 3· NCT07064486· Registry history of NCT07064486 on ClinicalTrials.gov (opens the registry)

   Oct 13, 2026

4. Notable

   BGM0504 Tablets in Overweight or Obese Participants Without…BGM0504 Tablets in Overweight or Obese Participants Without Diabetes

   Recruitment opened

   BrightGene Bio-Medical Technology Co., Ltd.·Phase 2· NCT07658560· Registry history of NCT07658560 on ClinicalTrials.gov (opens the registry)

   Oct 15, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.